Home > Documents in Process > FBXO7 Pathogenic Variants in Early-Onset Parkinsonism: Insights from a Neuroimaging Perspective and Review of the Literature. > print

001     282325
005     20251119165452.0
024 7 _ |a 10.1002/mdc3.70269
|2 doi
024 7 _ |a pmid:40740144
|2 pmid
024 7 _ |a pmc:PMC12625086
|2 pmc
037 _ _ |a DZNE-2025-01286
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Şahin, Erdi
|0 0000-0002-5792-2888
|b 0
245 _ _ |a FBXO7 Pathogenic Variants in Early-Onset Parkinsonism: Insights from a Neuroimaging Perspective and Review of the Literature.
260 _ _ |a New York, NY
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763567584_11058
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Early onset parkinsonism caused by F-box only protein7 (FBXO7) pathogenic variants is a rare autosomal recessive disorder presenting with a combination of parkinsonism, pyramidal signs, dystonia, cognitive impairment, and psychiatric features. Although previous case reports have mentioned neuroimaging findings, there is no comprehensive study characterizing the radiological spectrum of FBXO7 pathogenic variants.Ten patients from seven families followed at two tertiary centers in Turkey were included. The cohort included six males and four females with a mean onset age of 21.1 years. Frontal atrophy was the most common MRI finding, followed by global cortical and cerebellar atrophy. One patient showed iron accumulation in the pallidum, and two exhibited severe dopaminergic deficit on DaTSCAN.Pathogenic variants in the FBXO7 gene have been identified in diverse populations over the past 15 years, contributing to a broader understanding of clinical and radiological spectrum. Global cortical atrophy has emerged as the most frequently reported neuroimaging finding in FBXO7-related parkinsonism.FBXO7 pathogenic variants are associated with heterogeneous neuroimaging findings. Frontal and global cortical atrophy are common, while iron deposition and DaTSCAN abnormalities offer additional diagnostic clues. Larger, longitudinal studies are necessary to establish specific imaging biomarkers for FBXO7-related neurodegeneration.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a FBXO7
|2 Other
650 _ 7 |a early‐onset
|2 Other
650 _ 7 |a genetic
|2 Other
650 _ 7 |a neuroimaging
|2 Other
650 _ 7 |a parkinsonism
|2 Other
650 _ 7 |a FBXO7 protein, human
|2 NLM Chemicals
650 _ 7 |a F-Box Proteins
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: genetics
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: diagnostic imaging
|2 MeSH
650 _ 2 |a Parkinsonian Disorders: pathology
|2 MeSH
650 _ 2 |a F-Box Proteins: genetics
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Neuroimaging
|2 MeSH
650 _ 2 |a Young Adult
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Adolescent
|2 MeSH
650 _ 2 |a Age of Onset
|2 MeSH
650 _ 2 |a Atrophy
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
700 1 _ |a Samanci, Bedia
|b 1
700 1 _ |a Yalçın Çakmaklı, Gül
|b 2
700 1 _ |a Lohmann, Ebba
|0 P:(DE-2719)2811891
|b 3
|u dzne
700 1 _ |a Güven, Gamze
|b 4
700 1 _ |a Gökalp, Ebru Erzurumluoğlu
|b 5
700 1 _ |a Gündüz, Ayşegül
|b 6
700 1 _ |a Başak, Ayşe Nazlı
|0 0000-0001-6977-2517
|b 7
700 1 _ |a Ertan, Sibel
|b 8
700 1 _ |a Elibol, Bülent
|b 9
700 1 _ |a Bilgiç, Başar
|b 10
700 1 _ |a Hanağası, Haşmet
|b 11
773 _ _ |a 10.1002/mdc3.70269
|g Vol. 12, no. 11, p. 1972 - 1980
|0 PERI:(DE-600)2772809-2
|n 11
|p 1972 - 1980
|t Movement disorders clinical practice
|v 12
|y 2025
|x 2330-1619
856 4 _ |u https://pub.dzne.de/record/282325/files/DZNE-2025-01286_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/282325/files/DZNE-2025-01286_Restricted.pdf?subformat=pdfa
|x pdfa
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2811891
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-10
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOV DISORD CLIN PRAC : 2022
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-10
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-10
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-10
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-10
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-10
920 1 _ |0 I:(DE-2719)1210000
|k AG Gasser
|l Parkinson Genetics
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1210000
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21